Multi-parametric hydrogels support 3D invitro bioengineered microenvironment models of tumour angiogenesis

Biomaterials

Volumn 53, Issue , 2015, Pages 609-620

  Bray, Laura J ^a,b   Binner, Marcus ^a   Holzheu, Anja ^a   Friedrichs, Jens ^a   Freudenberg, Uwe ^a   Hutmacher, Dietmar W ^b   Werner, Carsten ^a  

^a CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Angiogenesis; Carcinogenesis; Cell culture; ECM; Heparin; Hydrogel

Indexed keywords

BIOMIMETICS; CELL CULTURE; CHEMOTHERAPY; DISEASES; HYDROGELS; MILITARY ELECTRONIC COUNTERMEASURES; PATHOLOGY; TUMORS;

ANGIOGENESIS; CANCER PROGRESSION; CARCINOGENESIS; HEPARIN; MULTIPLE CELL TYPES; THERAPEUTIC TARGETS; THREEDIMENSIONAL (3-D); TWO DIMENSIONAL (2 D);

DIAGNOSIS;

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AXITINIB; DOXORUBICIN; EPIRUBICIN; GLYCOSAMINOGLYCAN; MATRIGEL; PACLITAXEL; PLERIXAFOR; ANTINEOPLASTIC AGENT; HYDROGEL;

ARTICLE; ATOMIC FORCE MICROSCOPY; BREAST CANCER CELL LINE; BREAST TUMOR; CELL CULTURE; CELLS BY BODY ANATOMY; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE TUMOR; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VASCULARIZATION; BIOLOGICAL MODEL; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; VASCULARIZATION;

ANIMALIA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; HYDROGELS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84927925587     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.124     Document Type: Article

References (37)

1. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
2. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat Mater 2010, 9:90-93.
3. Cukierman E., Pankov R., Yamada K.M. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002, 14:633-639.
4. Vogel V., Sheetz M. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol 2006, 7:265-275.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
7. Chwalek K., Bray L.J., Werner C. Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. Adv Drug Deliv Rev 2014, 79-80:30-39.
8. Correa de Sampaio P., Auslaender D., Krubasik D., Failla A.V., Skepper J.N., Murphy G., et al. Aheterogeneous invitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One 2012, 7. e30753.
9. Janvier R., Sourla A., Koutsilieris M., Doillon C.J. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res 1997, 17:1551-1557.
10. Freudenberg U., Hermann A., Welzel P.B., Stirl K., Schwarz S.C., Grimmer M., et al. Astar-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. Biomaterials 2009, 30:5049-5060.
11. Tsurkan M.V., Chwalek K., Prokoph S., Zieris A., Levental K.R., Freudenberg U., et al. Defined polymer-peptide conjugates to form cell-instructive starPEG-heparin matrices in situ. Adv Mater 2013, 25:2606-2610.
12. Chwalek K., Tsurkan M.V., Freudenberg U., Werner C. Glycosaminoglycan-based hydrogels to modulate heterocellular communication in invitro angiogenesis models. Sci Rep 2014, 4:4414.
13. Weis J.R., Sun B., Rodgers G.M. Improved method of human umbilical arterial endothelial cell culture. Thromb Res 1991, 61:171-173.
14. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., et al. Mesenchymal stem cells can be differentiated into endothelial cells invitro. Stem Cells 2004, 22:377-384.
15. Krieg M., Arboleda-Estudillo Y., Puech P.H., Kafer J., Graner F., Muller D.J., et al. Tensile forces govern germ-layer organization in zebrafish. Nat Cell Biol 2008, 10:429-436.
16. Hutter J., Bechhoefer J. Calibration of atomic-force microscope tips. Rev Sci Instrum 1993, 64:1868.
17. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., et al. Engineering tumors with 3D scaffolds. Nat Methods 2007, 4:855-860.
18. Friedrich J., Ebner R., Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 2007, 83:849-871.
19. ElBayoumi T.A., Torchilin V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy invivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009, 15:1973-1980.
20. El-Zawahry A., McKillop J., Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 5:2.
21. Graeser R., Chung D.E., Esser N., Moor S., Schachtele C., Unger C., et al. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int J Cancer 2008, 122:1145-1154.
22. Zhang Y., Song S., Yang F., Au J.L., Wientjes M.G. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. JPharmacol Exp Ther 2001, 299:426-433.
23. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
24. Ingthorsson S., Sigurdsson V., Fridriksdottir A., Jonasson J.G., Kjartansson J., Magnusson M.K., et al. Endothelial cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. BMC Res Notes 2010, 3:184.
25. Kolesky D.B., Truby R.L., Gladman A.S., Busbee T.A., Homan K.A., Lewis J.A. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater 2014, 26:3124-3130.
26. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. Invitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors. Tissue Eng Part C Methods 2013, 19:864-874.
27. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
28. Sieh S., Taubenberger A.V., Rizzi S.C., Sadowski M., Lehman M.L., Rockstroh A., et al. Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One 2012, 7. e40217.
29. Weigelt B., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev 2014, 69-70:42-51.
30. Ma J., Waxman D.J. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 2009, 15:578-588.
31. Borgstrom P., Gold D.P., Hillan K.J., Ferrara N. Importance of VEGF for breast cancer angiogenesis invivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999, 19:4203-4214.
32. Domanska U.M., Timmer-Bosscha H., Nagengast W.B., Oude Munnink T.H., Kruizinga R.C., Ananias H.J., et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012, 14:709-718.
33. Cho K.S., Yoon S.J., Lee J.Y., Cho N.H., Choi Y.D., Song Y.S., et al. Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model. Oncol Lett 2013, 6:933-938.
34. Bolitho C., Xu W., Zoellner H. Negative feedback for endothelial apoptosis: a potential physiological role for fibroblast growth factor. JVasc Res 2008, 45:193-204.
35. Ishikawa M., Inoue T., Shirai T., Takamatsu K., Kunihiro S., Ishii H., et al. Simultaneous expression of cancer stem cell-like properties and cancer-associated fibroblast-like properties in a primary culture of breast cancer cells. Cancers 2014, 6:1570-1578.
36. Reis-Filho J.S., Simpson P.T., Turner N.C., Lambros M.B., Jones C., Mackay A., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006, 12:6652-6662.
37. Udayakumar T.S., Bair E.L., Nagle R.B., Bowden G.T. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression. Mol Carcinog 2003, 38:70-77.